Key Topics for SMi’s Ophthalmic Drugs Conference Released

SMi Group reports: Hear from industry experts at the 4th annual Ophthalmic Drugs Conference convening on 22nd & 23rd November 2021 in London. End Quote

(1888PressRelease) July 01, 2021 - The Ophthalmic Drugs conference will bring together expertise from individuals in multiple disciplines of the field. The packed agenda will offer a series of presentations, through which will provide insight into new industry developments and clinical trials, innovations in the treatment of rare diseases, regulatory perspectives, and advances in gene therapy.

Download the brochure to see full agenda and speaker line-up: www.ophthalmicdrugs.com/pr21888

Key presentations will be held throughout the conference from leading ophthalmic companies such as: ProQr therapeutics, Boehringer Ingelheim SparingVision, Roche, Genentech, Bayer, Eyevensys, Oxurion NV, Gensight-Biologics, ForwardVue pharma, InflammX Therapeutics.

Below are key topics that will be presented at this year’s Ophthalmic Drugs conference:
• Port Delivery System with Ranibizumab: A surgery, device, drug combination product
• Design and characteristics of a sustained release local ocular formulation of carboxyamidotriazole, a safe and effective antiangeogenic with a novel mechanism of action
• New mechanism of action anti-inflammatory analgesic for the treatment of ocular pain
• For topical Drug Delivery to the retina — Design the right Drug
• From the trabecular meshwork to the retina – Ophthalmological research at aerie
• Novel upstream target inhibiting the NLRP3 inflammasome in geographic atrophy and diabetic retinopathy
• Diabetic macular ischaemia: a hidden unmet medical need
• Childhood myopia: a pediatric eye disease at an epidemic scale
• Ocular tolerability and formulation toxicity in drug development
• Patient centricity as a driver for drug delivery innovation in ophthalmology
• Ocular gene therapy
• Development of lumevoq gene therapy in leber hereditary Optic Neuropathy (LHON) subjects
• Advancements in treatments for inherited retinal diseases
• Genetic therapy for inherited retinal diseases
• Non-viral gene therapy for the prolonged delivery of proteins in the eye
• Ocular delivery of small molecules and biologics using long-acting injectable photocrosslinked implants
• Nanomaterials for posterior segment drug delivery
• Recent advancements in the formulation and delivery of apis to the ocular surface and anterior segment of the eye
• Innovative pathways and compounds for improved therapies of retinal vascular disorders (DME, wet AMD, RVO): Beyond anti-VEGF
• Clinical development and regulatory landscape for ophthalmic products in UK and Europe

Register online www.ophthalmicdrugs.com/pr21888

Proudly Sponsored by: EXPERIMENTICA and TALLC

For media queries please contact Jinna Sidhu at hsidhu ( @ ) smi-online dot co dot uk or call +44 (0)20 7827 6088

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses, and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

###

space

Other Related Press Releases